A safety and immune response study to evaluate varying doses of an mRNA vaccine against Coronavirus disease 2019 (COVID-19) in healthy adults

Trial Identifier: 219112
Sponsor: GlaxoSmithKline
Start Date: August 2023
Primary Completion Date: May 2024
Study Completion Date: October 2024
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, CA San Diego, CA, United States, 92108
United States, FL Melbourne, FL, United States, 32934
United States, IL Peoria, IL, United States, 61614
United States, TX Austin, TX, United States, 78705